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Introduction
The ability to exercise, or exercise capacity, is an evolutionarily 
conserved physiological function of vital importance because it 
allows animals living in the wild to escape danger. In addition, 
exercise provides numerous health benefits to the general popula-
tion. This explains why there is a growing interest in understanding 
how this physiological process is regulated (1, 2). Several cytokines 
have been shown to favor muscle function during exercise and as 
a result to increase exercise capacity (3). One of them, interleu-
kin 6 (IL-6), sees its circulating levels surge during exercise (4–8). 
Because Il6 is expressed by many cell types, this raises the ques-
tion of the identity of the cell type(s) responsible for its increase in 
the general circulation during exercise. It has been proposed that 
once secreted into the general circulation, IL-6 enhances exercise 
capacity by promoting gluconeogenesis and lipolysis, i.e., the pro-
duction of the 2 main nutrients for myofibers (3, 7, 9–12). Howev-
er, this mechanism of action has not been verified in vivo, which 
leaves open the possibility that IL-6 could regulate exercise capac-
ity through other, yet to be described, means. Those 2 questions 
are of paramount importance if we want to achieve a comprehen-
sive understanding of how exercise capacity is regulated.
Hormones signaling in myofibers can also contribute to the 
increase in muscle function during exercise. In that regard, we 
have shown, through its injections in wild-type (WT) mice and 
the analysis of mice lacking its receptor only in myofibers, that 
the bone-derived hormone osteocalcin is necessary and sufficient 
to increase muscle function during exercise in the mouse (13). 
Osteocalcin also promotes the rise in Il6 expression in muscle and 
in circulating IL-6 levels during exercise. On the other hand, in cell 
culture experiments, IL-6 increased the expression in osteoblasts 
of Rankl, a gene necessary for osteoclast differentiation, a process 
that is required for the generation of the uncarboxylated and bio-
active form of osteocalcin (13–15).
Altogether, the functions of IL-6 during exercise and the rela-
tionship between osteocalcin and muscle-derived IL-6 (mIL-6) 
raise the following questions regarding the mechanism(s) where-
by IL-6 promotes exercise capacity: To what extent does muscle 
contribute to the rise in circulating IL-6 during exercise? Does 
mIL-6 enhance exercise capacity on its own? If it does, what is 
its mechanism of action? Can we provide evidence that regulato-
ry events identified in the mouse also take place in humans? The 
present study was conducted to address these questions.
Results
IL-6 is necessary for the increase in circulating osteocalcin levels 
observed in response to a training intervention in humans. If the 
interplay identified in the mouse and taking place during exercise 
between IL-6 and osteocalcin is of real physiological significance 
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For that purpose we crossed Il6fl/fl mice with Hsa-MerCreMer 
mice that express the Cre recombinase in an inducible manner spe-
cifically in myofibers (Figure 2A and refs. 16, 17). Cre expression 
was induced in 5-week-old mice by intraperitoneal (i.p.) injections 
of tamoxifen (10 mg/mL) 4 days in a row followed by feeding with 
tamoxifen-containing chow diet (1 mg/20 g of body weight) for 2 to 
4 weeks before analysis (18). This resulted in a highly efficient dele-
tion of Il6 in oxidative (soleus), glycolytic (extensor digitalis or EDL), 
and mixed-fiber muscle (gastrocnemius). In contrast, no deletion of 
Il6 could be detected in the heart or any other tissues tested (Figure 
2, B and C). Il6Hsa–/– mice were obtained at the expected Mendelian 
ratio, had a normal life span, and appeared overtly normal.
The contribution of muscle to circulating IL-6 levels during 
exercise was assessed by measuring its levels in male and female 
Il6Hsa–/– and control mice before and after exercise (running on a 
treadmill at a constant speed until exhaustion or for 50 minutes) 
(13). We observed that although circulating IL-6 levels increased 
robustly in control mice after exercise, they did not in Il6Hsa–/– mice 
(Figure 2D and Supplemental Figure 1, A and B). These results 
indicate that the vast majority of the IL-6 molecules present in 
general circulation during exercise originate from muscle.
The extent to which mIL-6 contributes to exercise capacity 
during an endurance exercise was determined by measuring the 
ability of Il6Hsa–/– and control mice to perform endurance running. 
Starting at 3 months of age, male and female Il6Hsa–/– mice exhib-
ited a significant reduction in the time and distance they run on 
a treadmill apparatus when compared with control littermates 
(Figure 2E and Supplemental Figure 1C). The defect in exercise 
capacity observed in Il6Hsa–/– mice was specific to endurance exer-
cise because grip strength was not affected by the inactivation 
of mIL-6 (Supplemental Figure 1, D and E). As inferred by these 
results, treating WT mice with an antibody against IL-6 signifi-
cantly decreased their exercise capacity (Figure 2F). The severity 
of the deficit in exercise capacity observed in Il6Hsa–/– mice was an 
incentive to explore its cellular and molecular bases.
in determining exercise capacity, it should be observed in other 
species, including primates (13). In a first test of this contention 
we found that, as it does in mice, a single injection of recombinant 
osteocalcin significantly increased circulating IL-6 levels in rats 
and more importantly from a clinical vantage point, in nonhuman 
primates (Figure 1, A–C).
These results led us to further expand our analysis and to mea-
sure circulating levels of bioactive osteocalcin in obese, nondiabetic 
human subjects that had either rested or had undergone a 12-week-
long aerobic training period (8). This 12-week training period con-
sisted of endurance exercise sessions (45 minutes of biking) 3 times 
a week. We used for that purpose a novel and sensitive ELISA that 
specifically measures circulating uncarboxylated and bioactive 
human osteocalcin (13, 14). This endurance exercise training pro-
tocol resulted in a 60% increase in circulating osteocalcin levels in 
these individuals compared with resting individuals. Of note, this 
increase was sustained for at least 2 days after the cessation of exer-
cise. To the best of our knowledge, this represents the first evidence 
that performing endurance exercise 3 times a week for a relative-
ly long period of time (3 months) is enough to induce a significant 
increase in circulating osteocalcin levels in humans (Figure 1D).
In the third experiment, we measured circulating osteocal-
cin levels in cohorts of exercising obese nondiabetic subjects that 
received either placebo or an anti–IL-6 receptor (anti–IL-6R) anti-
body (tocilizumab) during the training period (8). We observed 
that in individuals that had received the anti–IL-6R antibody, the 
increase in circulating osteocalcin levels triggered by exercise had 
virtually disappeared (Figure 1D). Albeit of a correlative nature, 
these latter data are an indication that IL-6 may regulate circulat-
ing osteocalcin levels in humans as well during exercise.
mIL-6 is needed for maximal exercise capacity. In view of the 
conservation of regulation between mice and humans present-
ed above, we asked to what extent does muscle contribute to the 
increase in circulating IL-6 levels observed during exercise and 
does mIL-6 actually regulate exercise capacity?
Figure 1. IL-6 is necessary for the increase in circulating osteocalcin levels observed in response to a training intervention in humans. (A–C) Circulating 
IL-6 levels in (A) rhesus monkeys (14 ± 0.8 years old), (B) rats (4 months old), and (C) mice (3 months old) treated with vehicle or osteocalcin (Ocn) (13.5 
ng/g for monkeys, 30 ng/g for rats, and 30 ng/g for mice). n = 12 per treatment. Statistical analyses were conducted using 1-way ANOVA followed by 
Tukey’s post hoc test (A) or 2-tailed unpaired t test (B and C). (D) Circulating uncarboxylated and bioactive Ocn levels in obese, nondiabetic subjects treat-
ed with either placebo or a neutralizing antibody against the IL-6 receptor in combination with or without intensive endurance exercise for 45 minutes, 3 
times a week, for 12 consecutive weeks. n = 11 per group except no exercise with the tocilizumab group, n = 12. Statistical analyses were conducted using 
1-way ANOVA followed by the Holm-Sidak post hoc test. All results presented as the mean ± SEM. *P < 0.05; **P < 0.01.
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control experiment, we observed that an injection of IL-6 before 
exercise increased circulating IL-6 levels, corrected as it should 
the deficit in exercise capacity observed in the Il6Hsa–/– mice, and 
restored the surge of circulating osteocalcin levels during endur-
ance exercise (Figure 3, D–F). This IL-6 injection also corrected the 
deficit in exercise capacity seen in Ocn+/– Il6Hsa+/– mice (Figure 3G). 
More importantly for our purpose, an injection of osteocalcin cor-
rected the majority of the deficit in exercise capacity seen in Il6Hsa–/– 
mice during endurance exercise. Of note, circulating Il-6 levels 
increased following these osteocalcin injections, suggesting that 
osteocalcin can release IL-6 from organs other than muscle (Fig-
ure 3, H and I). These data support the notion that osteocalcin is a 
mediator of mIL-6’s ability to enhance exercise capacity without 
excluding the possibility that other mediators of this action exist.
mIL-6 favors exercise capacity in part through osteocalcin. 
Although trying to unravel how mIL-6 enhances exercise capacity, 
we observed that circulating osteocalcin (encoded by the Ocn gene) 
levels did not increase in Il6Hsa–/– mice after exercise, as they did in 
control mice (Figure 3A). Moreover, Ocn+/– Il6Hsa+/– mice exhibited a 
deficit in exercise capacity as severe as the one observed in Il6Hsa–/– 
mice, whereas single heterozygous mice did not, and that circu-
lating osteocalcin did not increase in Ocn+/– Il6Hsa+/– mice during an 
endurance exercise. This genetic epistasis experiment indicated 
that osteocalcin mediates mIL-6 regulation of adaptation to exer-
cise in the mouse, as it appears to do in humans (Figure 3, B and C).
If the aforementioned hypothesis is accurate, then one would 
expect that osteocalcin would correct, at least in part, the deficit 
in exercise capacity observed in mice lacking mIL-6. In a positive 
Figure 2. Muscle-derived IL-6 is needed for maximal exercise capacity. (A) The promoter of the human α-skeletal actin (HSA) gene drives expression of the 
MerCreMer (MCM) gene, which harbors a mutated estrogen receptor (Mer) ligand-binding domain on each end of Cre recombinase. After crossing with Il6fl/fl  
mice and treatment with tamoxifen, a Cre-mediated recombination event results in the deletion of the Il6 gene. (B) Detection of Il6 deletion by PCR on 
genomic DNA isolated from various tissues of Il6Hsa
–/– mice. (C) Detection of Il6 deletion by PCR on genomic DNA isolated from various skeletal muscles of  
Il6Hsa
–/– mice. (D) Circulating IL-6 levels in 3-month-old male Il6fl/fl and Il6Hsa–/– mice at rest and after exercise. n = 8 per group. (E) Performance during an endur-
ance run of 3- and 6-month-old Il6fl/fl and Il6Hsa
–/– female mice. (F) Performance during an endurance test (running on a treadmill at 30 cm/s until exhaustion) 
of 8-month-old mice treated with vehicle or osteocalcin (Ocn, 500 ng/g) and an antibody against IL-6 or a control IgG, n = 7 per group. Results presented as the 
mean ± SEM. Data were analyzed with 2-tailed unpaired t test (D and E) or 1-way ANOVA followed by Tukey’s post hoc test (F) *P < 0.05; **P < 0.01.
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in the weight of oxidative muscles, e.g., the soleus, the most mobi-
lized muscle type during an endurance exercise, in 3-month-old 
Il6Hsa–/– mice compared with control littermates (Figure 4A). One 
experimental line of evidence indicates, however, that mIL-6 reg-
ulates muscle function independently of its regulation of muscle 
mIL-6 contributes to the maintenance of muscle mass in an 
osteocalcin-independent manner. In the course of this analysis we 
observed a second muscle phenotype in Il6Hsa–/– mice. Indeed, and 
even though myostatin (Mstn) expression was not affected (Sup-
plemental Figure 1E), Il6Hsa–/– mice exhibited a significant decrease 
Figure 3. mIL-6 favors exercise capacity in part through osteocalcin. (A) Circulating bioactive osteocalcin (Ocn) levels in 3-month-old Il6fl/fl and Il6Hsa–/–  
mice at rest and after exercise, n = 12. (B) Performance during an endurance run of 3-month-old Ocn+/– Il6Hsa+/– and control (Il6Hsa+/–, Ocn+/–, and WT) 
mice, n = 8–12. (C) Circulating Ocn levels in 3-month-old control (Il6fl/fl, Ocn+/–, and WT mice) and Ocn+/– Il6Hsa+/– mice at rest and after exercise, n = 8. (D) 
Performance during an endurance run of 3-month-old Il6fl/fl and Il6Hsa
–/– mice after an i.p. injection of IL-6 (3 ng/g), n = 8. (E) Circulating Ocn levels during 
an endurance run in 3-month-old Il6fl/fl and Il6Hsa
–/– mice after an i.p. injection of IL-6 (3 ng/g), n = 8. (F) Circulating IL-6 levels during an endurance run in 
3-month-old Il6fl/fl and Il6Hsa
–/– mice after an i.p. injection of IL-6 (3 ng/g), n = 8. (G) Performance during an endurance run of 3-month-old control (Il6fl/fl, 
Ocn+/–, and WT mice) and Ocn+/– Il6Hsa
+/– mice after an i.p. injection of IL-6 (3 ng/g), n = 8. (H) Performance during an endurance run of 3-month-old Il6fl/fl 
and Il6Hsa
–/– mice after an i.p. Ocn injection (120 ng/g), n = 7. (I) Circulating IL-6 levels during an endurance run in 3-month-old Il6fl/fl and Il6Hsa–/– mice after 
an i.p. injection of Ocn (120 ng/g), n = 8. These results are representative of 3 independent experiments. Data were analyzed by 1-way ANOVA followed by 
Tukey’s post hoc test. Results presented as the mean ± SEM. *P < 0.05; **P < 0.01.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 8 9 2 jci.org   Volume 130   Number 6   June 2020
Figure 4. mIL-6 contributes to the maintenance of muscle mass in an osteocalcin-independent manner. (A) Weight of hind limb muscles of 3-month-old 
female Il6Hsa
–/– and control littermates, n = 6–11. (B) Weight of hind limb muscles in 3-month-old Ocn+/– Il6Hsa+/– compound mutant mice and control litter-
mates (control group includes WT, Ocn+/–, and Il6Hsa
+/– mice), n = 5–7. (C) Representative H&E staining of soleus muscle fibers in 3-month-old female Il6Hsa–/– 
and control littermates. Scale bars: 100 μm. (D and E) Representative histology with (D) N0Q7 (MHC I slow twitch fibers) and (E) MY32 (MHC II fast twitch 
fibers) staining of soleus muscle of 3-month-old female Il6Hsa
–/– and control littermates. Scale bars: 100 μm. (F) Distribution of type 1 and type II myofibers 
in 3-month-old female Il6Hsa
–/– and control littermates. Scale bars: 100 μm. (G) Measurement of cross-sectional area (CSA) of muscle fibers in 3-month-old 
female Il6Hsa
–/– and control littermates. (H) Expression of myosin heavy chain genes in gastrocnemius muscle measured by qRT-PCR. (I) Representative 
histology with N0Q7 and MY32 staining of soleus muscle after endurance exercise in 3-month-old female Il6Hsa
–/– and control littermates. Scale bars: 100 
μm. These results are representative of 3 independent experiments. Data shown in A, F, and G were analyzed by 2-tailed unpaired t test and data in B and 
H by 1-way ANOVA followed by Tukey’s post hoc test. Data are presented as the mean ± SEM. *P < 0.05.
